Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. - Wikidata - awgldk - TriplyDB

Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes.

Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes.

http://www.wikidata.org/entity/Q35229766

about

New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases.Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology ACE2 improves right ventricular function in a pressure overload model.The past, present and future of renin-angiotensin aldosterone system inhibition Angiotensin converting enzyme (ACE) and ACE2 bind integrins and ACE2 regulates integrin signalling.Association of plasma angiotensin-(1-7) level and left ventricular function in patients with type 2 diabetes mellitus ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury ACE2 is augmented in dystrophic skeletal muscle and plays a role in decreasing associated fibrosis.Combination of angiotensin-(1-7) with perindopril is better than single therapy in ameliorating diabetic cardiomyopathy.Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit.Angiotensin-converting enzyme 2: the first decade.Protective Role of the ACE2/Ang-(1-9) Axis in Cardiovascular Remodeling.ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure.ACE2 alterations in kidney disease.Angiotensin-converting enzyme 2 as a therapeutic target for heart failure New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism.Novel neurohormonal insights with therapeutic potential in chronic heart failure.Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy.Role of ACE2 in diastolic and systolic heart failure.The ACE2 gene: its potential as a functional candidate for cardiovascular disease.Emerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in?Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications.Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets.Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases.BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure.Emerging biomarkers for heart failure: an update.Update on the role of angiotensin in the pathophysiology of coronary atherothrombosis.ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension.Future drug discovery in renin-angiotensin-aldosterone system intervention.Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.Antenatal corticosteroids and the renin-angiotensin-aldosterone system in adolescents born preterm.Tissue-specific pattern of angiotensin-converting enzyme 2 expression in rat pancreas.Angiotensin-converting enzyme 2 activity in patients with chronic kidney disease.Circulating ACE2 activity correlates with cardiovascular disease development.Serum levels of renin-angiotensin system components in acute stroke patients.Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease.

P2860

Q28541744-71343CE1-A8AD-4AD3-BE11-2E7DBC329300 Q33677369-F5717088-5F58-4104-B7C5-726503EB787C Q33748856-8EDBA257-1ABB-4B40-ABB2-D6532236B3BF Q33939495-7AD1C0A4-85F6-4CFE-8B82-F559470C400D Q34094354-277FF07D-71E2-4A3F-A7D8-5E2B2ADF277E Q34241697-EADA5EED-C6B4-4439-BA65-630B6B5F6695 Q34729883-DDFC4519-9EC4-46EB-8280-F5B198B18708 Q34866649-6DA4DD57-9E9E-41FF-9A93-431635030D49 Q35138448-21CAA13F-3307-46D6-925F-4C04BC6ABC89 Q35148756-9AA58D2A-FDFC-4B2F-8906-F449C55AAA40 Q35152116-4219EE99-722E-4368-9433-521232D04D27 Q35550937-3693952D-88EA-4741-B722-C04DA36F5084 Q35726197-743B5324-D835-41E6-B5EC-9CDFE2F14B45 Q35760437-72F8E758-849C-46A5-B102-5566CF6829E5 Q36699651-A14CB563-A5E0-44C8-B108-E39D7E25FB6A Q37194713-EAAD9294-DF10-4440-90BC-9BB6EC8B21AA Q37262837-95C21254-CF98-4F5B-935E-EC130DD7FD56 Q37620934-78114CBD-4B79-40A2-A66D-4989D76BD37A Q37660786-403EB9B9-AE03-4C3F-B1ED-B44B5326C68A Q37749836-A01EAEDF-D5D5-4C6E-8BA2-382822E86605 Q37879608-CA9224D0-11ED-4B8F-AEB8-702DC7A7B021 Q37884450-D438ECFC-95D1-45D4-8422-B81258D8E81D Q38046618-2BAA9181-7B60-4D97-B92D-D0F3714B3817 Q38083745-9BAA99D1-9588-4F88-8D6F-DC2E8D70F9B9 Q38170474-8AE03C90-6C30-4246-976F-A2CA8BA12924 Q38207841-3FCFA156-F775-47FF-8FA5-7F029B851F94 Q38214892-F18D84F6-96A2-4CD7-8D88-4755F692B1FD Q38225445-2715B778-B5A9-47CC-BD20-0278C445BDD2 Q38249995-D8535662-71FD-4852-AE1A-A962B97EDCDD Q38317550-8B66ECD4-5A0E-49FB-A353-46DA5337A244 Q38567063-C5161234-C717-40AA-9E58-392F557F11B4 Q38679303-C6AB16D8-296C-473E-AE9D-610D316E98B6 Q39599579-ACF2B440-6EA7-44BB-8881-D47168CD4C95 Q42379947-68C856E2-225B-4572-8BC2-4B9CD49E0A1E Q43048717-952811EE-AA07-450F-BDDC-D06169C5646E Q44428408-5F59688A-6816-4206-A5AC-DA203198FFDD Q48396569-A6768969-F58C-4127-917F-16A86370F4FC Q48844140-1D0E18BE-B5BA-4960-8A11-AB6FB818F03B Q55409649-C99CC987-2BBD-4599-9BF5-43A8E7A69432

P2860

Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes.

http://www.wikidata.org/entity/Q35229766

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Soluble angiotensin-converting ...... unction and clinical outcomes.

@ast

Soluble angiotensin-converting ...... unction and clinical outcomes.

@en

type

label

Soluble angiotensin-converting ...... unction and clinical outcomes.

@ast

Soluble angiotensin-converting ...... unction and clinical outcomes.

@en

prefLabel

Soluble angiotensin-converting ...... unction and clinical outcomes.

@ast

Soluble angiotensin-converting ...... unction and clinical outcomes.

@en

P1433

Q35229766-9B899171-994A-4E73-8EE3-F78FF3E643E0

P1476

Q35229766-A022B57E-58BC-48C8-B56B-27CFEF1EB133

P2093

Q35229766-1C327F5E-2DDA-408F-84E5-54755D27FA3D

Q35229766-2B3EA59F-C2A3-4450-AC86-E67840589485

Q35229766-47FE1BEA-A2D3-4C79-8774-EFB8BD6F7CF6

Q35229766-ABB08F86-D87C-48C7-A899-A0DC01D3AF05

Q35229766-EA10F538-0AB2-401A-B166-0DF7EBC7A571

P2860

Q35229766-041172C0-AFDF-4A3D-9A04-4344CFEBE1D5

Q35229766-1A294A53-9CC8-4AFA-953D-9B757D604B0B

Q35229766-22CBEA81-DEE2-468C-8B2C-C07B4B6F755E

Q35229766-41027892-111F-4EA8-998F-44D291C429D0

Q35229766-5A6B72E8-0D48-4D82-9688-4A43151C0ACB

Q35229766-5EAC3509-5074-4CF8-B210-0E41B81CF488

Q35229766-6A5F785F-70E8-41DA-90D3-27747F9B9D6C

Q35229766-89F818FD-7E49-452D-B3DF-DA3D8A52B4FA

Q35229766-9504C694-F951-425E-855F-1BC080BC7720

Q35229766-9C8CE3D0-28B1-40D7-BE5C-D0B05D80D4FC

P304

Q35229766-08055C61-1BB5-4156-A220-EAC391E28C6D

P31

Q35229766-E7A70E86-2C38-4FB3-8860-6D6694F0AD16

P356

Q35229766-843F326A-7A59-4C6F-985A-59BDC3D08FC7

P433

Q35229766-7647A254-F3AB-47F5-A037-0C1C4ADCA80C

P478

Q35229766-63EABC72-701A-4AE9-ABF3-CFC6997E32F5

P50

Q35229766-1398BC50-9E74-4114-A52C-E285A98FFDE4

Q35229766-167B19A6-301A-49CB-AF7C-70C14615FDB4

P577

Q35229766-B64049EB-92A9-4AB5-94A8-DE9B5ABDF66A

P5875

Q35229766-4A03C56D-2F77-4607-8862-69D38C2846F8

P698

Q35229766-8C341414-D91B-4493-ADAD-CE46430BC7B9

P921

Q35229766-B05F1E16-2BF2-447D-AC32-C5BF34226A69

P932

Q35229766-911A28C1-DF26-4CDA-8A4F-28AF8A92E3B6

P356

J.CARDFAIL.2009.01.014

P1433

Journal of Cardiac Failure

P1476

Soluble angiotensin-converting ...... function and clinical outcomes

@en

P2093

Allan L Klein

http://www.w3.org/2001/XMLSchema#string

Gary S Francis

http://www.w3.org/2001/XMLSchema#string

Kevin Shrestha

http://www.w3.org/2001/XMLSchema#string

Subha Sen

http://www.w3.org/2001/XMLSchema#string

W H Wilson Tang

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism

Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas

ACE2 gene expression is up-regulated in the human failing heart

Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase

Angiotensin-converting enzyme 2 is an essential regulator of heart function

Novel peptide inhibitors of angiotensin-converting enzyme 2.

Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

ACE2: A novel therapeutic target for cardiovascular diseases.

Myocardial proteases and matrix remodeling in inflammatory heart disease.

P304

565-571

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CARDFAIL.2009.01.014

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Richard W. Troughton

P577

2009-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26760486

http://www.w3.org/2001/XMLSchema#string

P698

19700132

http://www.w3.org/2001/XMLSchema#string

P921

P932

3179261

http://www.w3.org/2001/XMLSchema#string